Japan's MHLW approves 367 generics, but what does this mean?

21 August 2013

Japan’s Ministry of Health Labor and Welfare (MHLW) approved 367 items of generic drugs last week. Launch of the approved generics will be in December when they are price listed into the National Health Insurance (NHI) reimbursement table, reports The Pharma Letter’s local analyst.

Based on the current rule, NHI price listing takes place twice a year in June and December. The NHI price listing of generics by MHLW is made upon manufacturers’ requests and confirmation of capability to maintain stable supply.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Generics